Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  Percent of class outstanding represented by the amount in row (11) is based on 27,445,682 shares of Common Stock outstanding as of October 8, 2026 as set forth in the Issuer's prospectus filed with the United States Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on October 8, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Percent of class outstanding represented by the amount in row (11) is based on 27,445,682 shares of Common Stock outstanding as of October 8, 2026 as set forth in the Issuer's prospectus filed with the United States Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on October 8, 2026.


SCHEDULE 13G



 
PFIZER INC. (13-5315170)
 
Signature:/s/ Madelyn D. Purcell
Name/Title:Madelyn D. Purcell/Assistant Secretary
Date:10/16/2026
 
PFIZER VENTURES (US) LLC (82-5524518)
 
Signature:/s/ Madelyn D. Purcell
Name/Title:Madelyn D. Purcell/Assistant Secretary
Date:10/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of October 16, 2026, by and between Pfizer and PVUS.


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-99.1